I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including ...

Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but ...

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous ...

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption.

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, ...

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the ...